Zwitterionic Polymer-Insulin Conjugate for Glucose-Responsive Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for compositions that effectively deliver insulin for the treatment of diabetes and other disorders, with existing methods lacking in efficiency and responsiveness to glucose levels.

Innovation Solution

Development of zwitterionic polymer-insulin-saccharide compositions that include a zwitterionic polymer, an insulin moiety, and a saccharide moiety, which are synthesized through polymerization reactions and can be glucose-responsive, using saccharide binding molecules like lectins to control insulin release based on glucose levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If existing insulin delivery methods are used, then insulin can be delivered to patients, but the delivery efficiency and responsiveness to glucose levels are insufficient

Engineering Contradiction:

Improveinsulin delivery efficiencyVSAvoidresponsiveness to glucose levels

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent changes the chemical parameters of insulin by conjugating it with zwitterionic polymers and saccharide moieties. This modification alters the insulin's properties to enable glucose-responsive behavior while maintaining its biological activity, thereby improving both delivery efficiency and responsiveness to glucose levels

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite material system consisting of insulin conjugated with zwitterionic polymer chains and saccharide moieties. This composite structure combines the therapeutic function of insulin with the glucose-sensing capability of the polymer-saccharide system, achieving both efficient delivery and glucose-responsive release

Inventive Principle:

Principle #40Composite materials

2Stability of the object's composition

If insulin is delivered continuously, then blood glucose levels can be maintained, but the inability to respond dynamically to changing glucose concentrations reduces treatment effectiveness

Engineering Contradiction:

Improveblood glucose level maintenanceVSAvoiddynamic response to glucose changes

Core Design Contradiction:

Stability of the object's compositionVSAdaptability or versatility

Solution Approach 1:

The patent introduces dynamic responsiveness to the insulin delivery system through the glucose-sensitive zwitterionic polymer-saccharide conjugate. The system transitions between different states based on glucose concentration, enabling dynamic adjustment of insulin release to match changing physiological conditions while maintaining overall blood glucose stability

Inventive Principle:

Principle #15Dynamics

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These compositions provide a controlled and responsive delivery of insulin, effectively managing blood glucose levels by facilitating insulin release at high glucose concentrations and preventing release at low concentrations, thus addressing the limitations of existing insulin delivery methods.

Implementation Method 1

using saccharide binding molecules like lectins to control insulin release based on glucose levels

Methodology Applied

Scientific EffectSaccharide binding: Adsorption

Data Source

PatentUS12257309B2Zwitterionic polymer-insulin compositions and related methods

Publication Date: 2025.03.25 WAYNE STATE UNIV

AI summary

Glucose-responsive zwitterionic polymer-insulin-saccharide compositions are provided according to aspects of the present disclosure which include a zwitterionic polymer, an insulin moiety, a saccharide moiety, and a saccharide binding molecule. Methods of use of glucose-responsive zwitterionic polymer-insulin-saccharide compositions according to aspects of the present disclosure include administration to human patients to alleviate conditions, such as diabetes, which are responsive to administration of insulin.